Figure 7.

Immunization with MS2-VD4.A results in decreased urogenital Chlamydia burden as compared to WT MS2 immunized controls. (A) Immunization schedule. Female Balb/c mice (n = 10/group) were immunized three times, 3 weeks apart with their respective vaccine. Mice were administered 2.5 mg of Depo-Provera before vaginal challenge with Luc-Cm. (B) Average radiance (p/s/cm²/sr) measured for MS2-VD4.A and WT MS2 on days 3 through 7 post infection. (C) Average radiance (p/s/cm²/sr) measured for MS2-VD4.B and WT MS2 on days 3 through 7 post infection. (D) Area under the curve (AUC) measured for average radiance on days 3 through 7 post infection for MS2-VD4.A and WT MS2. (E) IVIS images for WT MS2 control mice (top), MS2-VD4.A mice (middle), and MS2-VD4.B mice (bottom) on day 7 post infection, with luminescence visualized, shown as a representative image of those collected each day. Statistical analysis was performed utilizing the nonparametric Mann–Whitney t-test. Quantitative data represent the geometric mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.